SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Liliʻuokalani

PatientLiliʻuokalani
Date of birth1947-09-02
IdentifiersMRN HR-ET024-SYN; SSN (made up) 000-24-3086
Document date2026-04-20
AuthorKealani Morrison-Takeda, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week review: rhythm monitor result and anticoagulation. [S]

History of Present Illness

Liliʻuokalani returns five weeks after the stroke, with a member of her ʻohana. The 30-day monitor recorded six episodes of atrial fibrillation, the longest 3 hours 10 minutes, about 3% of the time, none of which she felt. She finished 21 days of aspirin and clopidogrel two weeks ago and now takes clopidogrel alone, with no bleeding. Her home blood pressure averaged 138/82 in the week after the stroke, so losartan 25 mg was started a week after the event; her home average is now 126/76. The potassium and creatinine check two weeks after starting losartan did not happen: the member of her household who drives her was away, and she did not want to trouble anyone. She has had no new neurological symptoms and plays the piano every morning. She has begun lomilomi with a practitioner at Ke Ola Mamo, who was told about her blood thinners. [S]

ElementDetail
Rhythm monitorParoxysmal atrial fibrillation: six episodes, longest 3 hours 10 minutes, burden about 3%; no symptoms
Antiplatelets21 days of aspirin and clopidogrel completed; clopidogrel alone since
Home blood pressureAverage 126/76 mmHg on losartan 25 mg
Missed testPotassium and creatinine two weeks after losartan not done; no ride
FunctionPlays the piano daily; no new symptoms

Review of Systems

SystemResultFinding
NeurologicalNegativeNo new weakness, numbness, speech, vision or balance problem
CardiovascularNegativeNo palpitations, breathlessness or fainting
HematologicNegativeNo bruising, bleeding gums, black stools or blood in the urine
MusculoskeletalNegativeNo muscle aches on atorvastatin

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency departmentOne tablet daily for 21 daysOral route2026-03-16 to 2026-04-06completedS
Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency departmentOne tablet dailyOral route2026-03-16 to 2026-04-20completedS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Apixaban 5 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-04-20activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height160cmS
2026-04-20Body weight57.8kgS
2026-04-20Body mass index (BMI) [Ratio]22.6kg/m2S
2026-04-20Systolic blood pressure130mm[Hg]S
2026-04-20Diastolic blood pressure78mm[Hg]S
2026-04-20Heart rate74/minS
2026-04-20Respiratory rate16/minS
2026-04-20Body temperature36.6CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-04-20Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-04-20Creatinine [Mass/volume] in Serum or Plasma0.86mg/dL0.59-1.04 mg/dLNormalS
2026-04-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M69mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-20Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-04-20Hemoglobin [Mass/volume] in Blood12.7g/dL11.6-15 g/dLNormalS
2026-04-20Platelets [#/volume] in Blood by Automated count22810*3/uL150-400 10*3/uLNormalS
2026-04-20Cholesterol [Mass/volume] in Serum or Plasma138mg/dL<=199 mg/dLNormalS
2026-04-20Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation64mg/dLGoal below 70 mg/dL after ischemic strokeNormalS
2026-04-20Cholesterol in HDL [Mass/volume] in Serum or Plasma56mg/dL>=50 mg/dLNormalS
2026-04-20Triglyceride [Mass/volume] in Serum or Plasma92mg/dL<=149 mg/dLNormalS
2026-04-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS

Physical Exam

Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 130/78, pulse 74 and regular; weight 57.8 kg
CardiovascularRegular rhythm; no murmur
NeurologicalSpeech fluent; no drift; normal fine finger movements; normal gait
SkinNo bruising

Problems

ProblemClinical statusVerificationCodeProvenance
Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0resolvedprovisional G45.9S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms.
Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a strokeactiveconfirmed I63.412S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D.
Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intakeactiveconfirmed I10S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources.
Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2activeconfirmed I48.0S — Synthetic finding on prolonged rhythm monitoring at five weeks.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic and at home (target below 130/80 mmHg) and weightEvery visitCompleted today130/78 mmHg; home average 126/76; 57.8 kg
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerAbout two weeks after starting, then every six monthsDeferredThe check due two weeks after losartan was started was missed: the member of her household who drives her was away, and she did not ask anyone else. Today, four weeks after the start, potassium is 4.5 mmol/L and creatinine 0.86 mg/dL (eGFR 69), both normal, so no harm resulted. Corrective action: tests drawn at clinic visits, or at home by the clinic's nurse
ImagingECG and prolonged rhythm monitoring for atrial fibrillationECG at baseline; at least 30 days of monitoring within six months of the eventCompleted today30 days of monitoring: paroxysmal atrial fibrillation, six episodes, burden about 3%
Medication safetyAntithrombotic therapy and adherenceEvery visitCompleted today21 days of dual antiplatelets completed; clopidogrel stopped today; apixaban 5 mg twice daily started
LaboratoryAnticoagulant safety: blood count, kidney function (creatinine clearance) and liver testsBefore starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her)Completed todayBefore apixaban: hemoglobin 12.7 g/dL, platelets 228, creatinine 0.86 mg/dL (creatinine clearance about 49 mL/min), ALT 22 U/L
LaboratoryLipid panel (LDL goal below 70 mg/dL)Four to twelve weeks after starting a statin, then every three to twelve monthsCompleted todayFive weeks on atorvastatin 40 mg: LDL 64 mg/dL, total cholesterol 138, HDL 56, triglycerides 92
ImagingCarotid and intracranial vessel imagingAt the event; follow-up only for treated or moderate or greater stenosisNot indicatedCarotid plaque under 50%; no follow-up imaging needed
ExaminationNeurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptomsWith any change; modified Rankin Scale at 90 daysCompleted todayNo new symptoms; examination normal
SurveyCognitive screen (MoCA)After the event, again within the first year, then periodicallyUp to dateMoCA 26 at the stroke clinic; repeat within the first year
SurveyDepression screen (PHQ-2, PHQ-9)At the first post-stroke visit, then at least yearlyUp to datePHQ-2 1 at the stroke clinic; PHQ-9 at three months
ExaminationFalls riskEvery visitCompleted todayNo falls; falls plan reviewed before starting an anticoagulant
Self-managementTobacco, alcohol and physical activityEvery visitCompleted todayNever smoker; alcohol rarely; walks daily
Self-managementBE FAST and calling 911Every visitCompleted todayReviewed
Self-managementCulturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic careEvery visitCompleted todayLomilomi at Ke Ola Mamo by her choice, with the practitioner told about her blood thinners; the decision on apixaban was hers, with her ʻohana present

Goal progress:

Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke (2024); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026)

Follow-up: Three-month review in eight weeks. Call for bleeding that will not stop, black stools or any fall with a blow to the head; call 911 for any BE FAST sign. Next scheduled visit 2026-06-15: three-month review after the stroke: function, mood, blood pressure, apixaban safety and falls. [S]